Hidehito Horinouchi/X
Feb 7, 2025, 14:07
Hidehito Horinouchi: iDFS reliably predicts final OS in breast cancer
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by Fabio Conforti et al. published in the Journal of Clinical Oncology:
“Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
iDFS is an acceptable surrogate endpoint to confidently anticipate the final OS.
Dr. Fabio Conforti.”
Authors: Fabio Conforti, Valentina Nekljudova, Isabella Sala, Richard Gelber, Sibylle Loibl et al.
More posts featuring Hidehito Horinouchi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 7, 2025, 16:01
Aug 7, 2025, 15:18
Aug 7, 2025, 14:35
Aug 7, 2025, 13:56
Aug 7, 2025, 13:43